/ADXS
ADXS Stock - Ayala Pharmaceuticals, Inc.
Healthcare|BiotechnologyOTC
$0.21+0.00%
+$0.00 (+0.00%) • Jan 13
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.23
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ADXS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.21 – $0.21
TARGET (TP)$0.24
STOP LOSS$0.19
RISK/REWARD1:1.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-1.32
52W High$0.80
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $13,000 | $250,000 | $3.24M | $253,000 | $2.33M |
| Gross Profit | N/A | $-64,000 | $-468,000 | $-1,032,000 | $1.05M |
| Gross Margin | 0.0% | -25.6% | -14.4% | -407.9% | 44.9% |
| Operating Income | $-36,266,000 | $-16,090,000 | $-18,786,000 | $-26,449,000 | $-17,711,000 |
| Net Income | $-48,072,000 | $-14,359,000 | $-17,862,000 | $-26,469,000 | $-17,792,000 |
| Net Margin | -369784.6% | -5743.6% | -551.3% | -10462.1% | -762.3% |
| EPS | $-7.99 | $-7.90 | $-11.07 | $-34.71 | $-93.60 |
Company Overview
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ADXSBeat Rate
44%
Last 9 quarters
Avg Surprise
-43.5%
EPS vs Estimate
Beats / Misses
4/4
1 met exactly
Latest EPS
$-4.10
Q1 2024
EPS Surprise History
Q2 22
+40.6%
$-1.90vs$-3.20
Q3 22
-19.7%
$-3.83vs$-3.20
Q4 22
No data
Q1 23
-246.6%
$-2.53vs$-0.73
Q2 23
No data
Q4 23
-38.0%
$-1.82vs$-1.32
Q4 23
No data
Q1 24
-222.8%
$-4.10vs$-1.27
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | Jun 5, 2025 | — | — | — | — |
Q2 2025 | May 29, 2025 | — | — | — | — |
Q1 2025 | Feb 28, 2025 | — | — | — | — |
Q4 2024 | Nov 29, 2024 | — | — | — | — |
Q3 2024 | Aug 29, 2024 | — | — | — | — |
Q2 2024 | Apr 16, 2024 | — | — | — | — |
Q1 2024 | Feb 12, 2024 | $-1.27 | $-4.10 | -222.8% | ✗ MISS |
Q4 2023 | Oct 30, 2023 | — | $-1.53 | — | — |
Q4 2023 | Oct 2, 2023 | $-1.32 | $-1.82 | -38.0% | ✗ MISS |
Q2 2023 | Jun 21, 2023 | — | $-1.67 | — | — |
Q1 2023 | Feb 10, 2023 | $-0.73 | $-2.53 | -246.6% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | — | $-5.27 | — | — |
Q3 2022 | Sep 12, 2022 | $-3.20 | $-3.83 | -19.7% | ✗ MISS |
Q2 2022 | Jun 8, 2022 | $-3.20 | $-1.90 | +40.6% | ✓ BEAT |
Q1 2022 | Mar 17, 2022 | $-3.20 | $-2.40 | +25.0% | ✓ BEAT |
Q1 2022 | Feb 14, 2022 | $-3.20 | $-3.20 | 0.0% | = MET |
Q3 2021 | Sep 10, 2021 | $-3.20 | $-1.60 | +50.0% | ✓ BEAT |
Q2 2021 | Jun 14, 2021 | $-4.00 | $-3.20 | +20.0% | ✓ BEAT |
Q1 2021 | Mar 16, 2021 | — | $-4.00 | — | — |
Q1 2021 | Jan 25, 2021 | — | $-7.37 | — | — |
Latest News
Loading news...
Frequently Asked Questions about ADXS
What is ADXS's current stock price?
Ayala Pharmaceuticals, Inc. (ADXS) is currently trading at $0.21 per share. The stock has moved +0.00% today.
What is the analyst price target for ADXS?
No analyst price targets are currently available for this stock.
What sector is Ayala Pharmaceuticals, Inc. in?
Ayala Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is ADXS's market cap?
Ayala Pharmaceuticals, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does ADXS pay dividends?
No, Ayala Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAAGH
America Great Health
$0.00
Mkt Cap: $0.0B
AGNPF
Algernon Pharmaceuticals Inc.
$0.05
Mkt Cap: $0.0B
AGTX
Agentix Corp.
$0.05
Mkt Cap: $0.0B
APLIF
Appili Therapeutics Inc.
$0.02
Mkt Cap: $0.0B
HESG
Health Sciences Group, Inc.
$0.00
Mkt Cap: $0.0B
IBOGF
Universal Ibogaine Inc.
$0.00
Mkt Cap: $0.0B
NMLSF
Restart Life Sciences Corp.
$0.07
Mkt Cap: $0.0B
RGBP
Regen BioPharma, Inc.
$0.01
Mkt Cap: $0.0B
RNUGF
ReNeuron Group plc
$0.00
Mkt Cap: $0.0B
VGLS
VG Life Sciences Inc.
$0.00
Mkt Cap: $0.0B
Explore stocks similar to ADXS for comparison